[go: up one dir, main page]

WO2001055107A3 - Aromatic amines and amides acting on the melanocortin receptors - Google Patents

Aromatic amines and amides acting on the melanocortin receptors Download PDF

Info

Publication number
WO2001055107A3
WO2001055107A3 PCT/GB2001/000356 GB0100356W WO0155107A3 WO 2001055107 A3 WO2001055107 A3 WO 2001055107A3 GB 0100356 W GB0100356 W GB 0100356W WO 0155107 A3 WO0155107 A3 WO 0155107A3
Authority
WO
WIPO (PCT)
Prior art keywords
aromatic amines
melanocortin receptors
amides
amides acting
acting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/000356
Other languages
French (fr)
Other versions
WO2001055107A2 (en
Inventor
Torbjoern Lundstedt
Anna Skottner
Elisabeth Seifert
Per Andersson
Larisa Kaulina
Klara Dikovskaya
Ilze Mutule
Felikss Mutulis
Jarl Wikberg
Igor Starchenkov
Jana Kreicberga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melacure Therapeutics AB
Original Assignee
Melacure Therapeutics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002056A external-priority patent/GB0002056D0/en
Priority claimed from GB0002058A external-priority patent/GB0002058D0/en
Application filed by Melacure Therapeutics AB filed Critical Melacure Therapeutics AB
Priority to AU2001228681A priority Critical patent/AU2001228681A1/en
Publication of WO2001055107A2 publication Critical patent/WO2001055107A2/en
Publication of WO2001055107A3 publication Critical patent/WO2001055107A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/40—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to novel aromatic amines and amides of general formula (I) and to the use of these amines and amides for the treatment of obesity, anorexia, inflammation, mental disorders and other diseases associated with the melanocortin receptors or related systems, e.g. the melanocyte stimulating hormones.
PCT/GB2001/000356 2000-01-28 2001-01-29 Aromatic amines and amides acting on the melanocortin receptors Ceased WO2001055107A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001228681A AU2001228681A1 (en) 2000-01-28 2001-01-29 Novel aromatic amines and amides acting on the melanocortin receptors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0002056A GB0002056D0 (en) 2000-01-28 2000-01-28 Novel aromatic amines
GB0002058A GB0002058D0 (en) 2000-01-28 2000-01-28 Novel aromatic amines
GB0002058.6 2000-01-28
GB0002056.0 2000-01-28

Publications (2)

Publication Number Publication Date
WO2001055107A2 WO2001055107A2 (en) 2001-08-02
WO2001055107A3 true WO2001055107A3 (en) 2002-01-17

Family

ID=26243512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/000356 Ceased WO2001055107A2 (en) 2000-01-28 2001-01-29 Aromatic amines and amides acting on the melanocortin receptors

Country Status (2)

Country Link
AU (1) AU2001228681A1 (en)
WO (1) WO2001055107A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3415A1 (en) 2000-08-31 2002-03-07 Chiron Corp GUANIDINOBENZAMIDES AS MC4-R AGONISTS.
CA2424222A1 (en) * 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
DK1385823T3 (en) 2001-04-09 2007-03-26 Novartis Vaccines & Diagnostic Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
EP1425029A4 (en) 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALOPEPTIDES
SG176310A1 (en) 2001-11-08 2011-12-29 Ortho Mcneil Pharm Inc Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US6858637B2 (en) 2002-03-28 2005-02-22 Neurogen Corporation Substituted biaryl amides as C5a receptor modulators
DE60333937D1 (en) 2002-05-23 2010-10-07 Novartis Vaccines & Diagnostic SUBSTITUTED QUINAZOLINONE COMPOUNDS
MXPA05006507A (en) * 2002-12-20 2006-02-17 Chemocentryx Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor.
WO2004112793A1 (en) 2003-05-23 2004-12-29 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
AU2004293012A1 (en) 2003-11-19 2005-06-09 Rustum S. Boyce Quinazolinone compounds with reduced bioaccumulation
WO2005059558A2 (en) * 2003-12-11 2005-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor mc4 (mc4)
CA2624683A1 (en) * 2005-10-06 2007-04-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2007141343A1 (en) 2006-06-09 2007-12-13 Action Pharma A/S Phenyl pyrrole aminoguanidine derivatives
GB0624987D0 (en) 2006-12-14 2007-01-24 Acure Pharma Ab Novel aminoguanidines as melanocortin receptor ligands
EP2278962B1 (en) 2008-02-21 2014-02-12 Janssen Pharmaceutica N.V. Methods for the treatment of dermatological disorders
CN103877423A (en) * 2014-04-08 2014-06-25 张利民 Medicine for treating wind-cold pneumorrhagia-nephritic syndrome
LT3773558T (en) 2019-05-10 2022-09-12 Synact Pharma Aps Combination treatment of arthritic disease
WO2022268825A1 (en) 2021-06-21 2022-12-29 Synact Pharma Aps Phenyl pyrrole aminoguanidine salts and formulations

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2049377A1 (en) * 1969-10-10 1971-04-22 S A Manufactures J R Bottu, Pans Pharmaceutical preparations
FR2073286A1 (en) * 1969-12-23 1971-10-01 Robert Et Carriere Labo Substd anilines - with antirheumatic analgesic and antiinflammatory activity
EP0017376A1 (en) * 1979-03-30 1980-10-15 Kissei Pharmaceutical Co. Ltd Phenylacetamide compounds and an analgesic composition containing them
US4468448A (en) * 1983-06-02 1984-08-28 Polaroid Corporation Photographic products and processes
US4579866A (en) * 1984-05-29 1986-04-01 Usv Pharmaceutical Corp. Phenylacetamides as anti-allergy, anti-asthma and anti-inflammatory agents
EP0277755A1 (en) * 1987-01-30 1988-08-10 Kissei Pharmaceutical Co. Ltd. 4H-quinolizin-4-one compounds exhibiting therapeutic activities
US4803063A (en) * 1987-04-16 1989-02-07 Atochem Process for the cyclic production of hydrogen peroxide
EP0318944A2 (en) * 1987-12-04 1989-06-07 EASTMAN KODAK COMPANY (a New Jersey corporation) Increasing dye transfer efficiency in dye-donor elements used in thermal dye transfer
EP0334538A1 (en) * 1988-03-25 1989-09-27 The Upjohn Company Therapeutically useful tetralin derivatives
US5180796A (en) * 1990-02-26 1993-01-19 Phillips Petroleum Company Derivatization of arylene sulfide polymers
US5288749A (en) * 1991-12-20 1994-02-22 Abbott Laboratories Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
EP0613879A1 (en) * 1991-05-20 1994-09-07 TSUMURA & CO. Phellodendrine analogs and allergy type iv suppressor containing the same as active ingredient
US5571832A (en) * 1992-11-13 1996-11-05 The United States Of America As Represented By The Department Of Health And Human Services Nitrogen-containing cyclohetero alkylamino aryl derivatives for CNS disorders
WO1997042230A1 (en) * 1996-05-03 1997-11-13 Warner-Lambert Company Rapid purification by polymer supported quench
WO1998007692A1 (en) * 1996-08-17 1998-02-26 Zeneca Limited 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
WO1998050029A1 (en) * 1997-05-07 1998-11-12 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
WO1999001423A1 (en) * 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO1999021571A1 (en) * 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
WO1999044987A1 (en) * 1998-03-05 1999-09-10 Agouron Pharmaceuticals, Inc. NON-PEPTIDE GnRH AGENTS
WO1999055679A1 (en) * 1998-04-28 1999-11-04 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
WO1999064002A1 (en) * 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2049377A1 (en) * 1969-10-10 1971-04-22 S A Manufactures J R Bottu, Pans Pharmaceutical preparations
FR2073286A1 (en) * 1969-12-23 1971-10-01 Robert Et Carriere Labo Substd anilines - with antirheumatic analgesic and antiinflammatory activity
EP0017376A1 (en) * 1979-03-30 1980-10-15 Kissei Pharmaceutical Co. Ltd Phenylacetamide compounds and an analgesic composition containing them
US4468448A (en) * 1983-06-02 1984-08-28 Polaroid Corporation Photographic products and processes
US4579866A (en) * 1984-05-29 1986-04-01 Usv Pharmaceutical Corp. Phenylacetamides as anti-allergy, anti-asthma and anti-inflammatory agents
EP0277755A1 (en) * 1987-01-30 1988-08-10 Kissei Pharmaceutical Co. Ltd. 4H-quinolizin-4-one compounds exhibiting therapeutic activities
US4803063A (en) * 1987-04-16 1989-02-07 Atochem Process for the cyclic production of hydrogen peroxide
EP0318944A2 (en) * 1987-12-04 1989-06-07 EASTMAN KODAK COMPANY (a New Jersey corporation) Increasing dye transfer efficiency in dye-donor elements used in thermal dye transfer
EP0334538A1 (en) * 1988-03-25 1989-09-27 The Upjohn Company Therapeutically useful tetralin derivatives
US5180796A (en) * 1990-02-26 1993-01-19 Phillips Petroleum Company Derivatization of arylene sulfide polymers
EP0613879A1 (en) * 1991-05-20 1994-09-07 TSUMURA & CO. Phellodendrine analogs and allergy type iv suppressor containing the same as active ingredient
US5288749A (en) * 1991-12-20 1994-02-22 Abbott Laboratories Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
US5571832A (en) * 1992-11-13 1996-11-05 The United States Of America As Represented By The Department Of Health And Human Services Nitrogen-containing cyclohetero alkylamino aryl derivatives for CNS disorders
WO1997042230A1 (en) * 1996-05-03 1997-11-13 Warner-Lambert Company Rapid purification by polymer supported quench
WO1998007692A1 (en) * 1996-08-17 1998-02-26 Zeneca Limited 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
WO1998050029A1 (en) * 1997-05-07 1998-11-12 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
WO1999001423A1 (en) * 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO1999021571A1 (en) * 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
WO1999044987A1 (en) * 1998-03-05 1999-09-10 Agouron Pharmaceuticals, Inc. NON-PEPTIDE GnRH AGENTS
WO1999055679A1 (en) * 1998-04-28 1999-11-04 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
WO1999064002A1 (en) * 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R.C. WEAST (EDITOR): "Handbook of Chemistry and Physics, 52nd edition", 1971, THE CHEMICAL RUBBER CO., CLEVELAND, OHIO, US, XP002171193 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds

Also Published As

Publication number Publication date
AU2001228681A1 (en) 2001-08-07
WO2001055107A2 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
WO2001055107A3 (en) Aromatic amines and amides acting on the melanocortin receptors
WO2001055106A3 (en) Novel melanocortin receptor agonists and antagonists
ECSP045081A (en) DERIVATIVES OF 1,8-NAFTIRIDINE AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
NO20035025D0 (en) Use of osteopontin for treatment and / or prevention of neurological disorders
IS6003A (en) Monoamine reuptake inhibitors for the treatment of central nervous system disorders
NO20034996D0 (en) New arylsus phonamide compounds for the treatment of obesity, type II diabetes and CNS disorders
EP1474139A4 (en) INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA
NO20041216L (en) Imidazole-4-carboxamide derivatives, preparation and use thereof for the treatment of obesity
ZA200309977B (en) Arylamines for the treatment of conditions associated with GSK-3.
WO2004009034A3 (en) Thiomolybdate analogues and uses thereof
GB2349570B (en) Compositions for treatment of disorders of the oesophagus associated with reflux
MXPA03010134A (en) Substituted cyclohexane-1,4-diamine derivatives.
WO2005007111A3 (en) Tetrahydroquinoline derivatives as cannabinoid receptor modulators
PL367264A1 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
IL161829A (en) 1,2,4 - thiadiazole derivatives, some of which are novel and pharmaceutical compositions comprising the same for treating disorders mediated by melanocortin receptor modulators
PL377296A1 (en) 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators
PL367142A1 (en) 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
NO20043085L (en) Methods and compositions for the treatment of central nervous system disorders
EP1625207A4 (en) Compounds for treatment of inflammation, diabetes and related disorders
DK1339406T3 (en) Piperazine derivatives, processes for their preparation and use thereof for the treatment of central nervous system disorders
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
HUP0201791A3 (en) The use of escitalopram for treatment of neurotic disorders
NO20054913L (en) Use of clustein for the treatment and / or prevention of peripheral neurological disorders
TW200503717A (en) Substituted 1,4-pyrazine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP